Mar 18, 2008 7:58am EDT OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib
Feb 25, 2008 9:18am EST OPKO Health and Pathogenics Announce Data Publication Demonstrating the Potential Utility of NCT in a Severe Eye Infection
Jan 14, 2008 8:00am EST OPKO Health Appoints Industry Veteran Dr. Naveed Shams as Chief Medical Officer
Dec 06, 2007 8:00am EST OPKO's Bevasiranib Named One of Most Promising Drugs Recently Entering Phase III Trials
Oct 30, 2007 9:49am EDT OPKO Health Acquires Rights to Innovative Ocular Product to Prevent Serious Eye Infections